Isomorphic Labs
Isomorphic Labs is an AI Protein & Enzyme Design company founded in 2021 and based in London, United Kingdom.
Isomorphic Labs was founded in 2021 by Demis Hassabis as a spinout of Google DeepMind, and is headquartered in London with offices in Cambridge, Massachusetts and Lausanne, Switzerland. With Google DeepMind it developed AlphaFold 3, released in May 2024, which models the structures and interactions of proteins and other biological molecules. Its drug design engine, IsoDDE, builds on that work to design and evaluate molecules across therapeutic areas and drug modalities, and its internal pipeline focuses on oncology and immunology. The company works with pharmaceutical partners under research collaborations: Eli Lilly, Novartis, which expanded its deal in February 2025, and Johnson & Johnson, which signed a multi-target collaboration on Jan. 20, 2026. It raised $600 million in its initial external round on March 31, 2025, led by Thrive Capital, and a $2.1 billion Series B on May 12, 2026, also led by Thrive, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
Isomorphic applies the Nobel-winning AlphaFold line of structure-prediction models, which earned Hassabis a share of the 2024 Nobel Prize in Chemistry, to designing drugs. Its collaborations with Eli Lilly, Novartis and Johnson & Johnson put AI-designed molecules into large pharmaceutical pipelines across small molecules and biologics. Its $2.1 billion Series B in May 2026 compares with the $130 million Chai Discovery raised in December 2025. Reuters reported on May 12, 2026 that Isomorphic expected to begin clinical trials by the end of 2026.
At a glance
Total raised
Undisclosed
Headcount
—
Headquarters
London
United KingdomFounded
2021
Status
Private
Subsector